Status:
COMPLETED
Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
This trial is conducted in Asia. The aim of the trial is to investigate the efficacy and safety of biphasic insulin aspart 50 (BIAsp 50) twice daily versus biphasic human insulin 50 (BHI 50) twice dai...
Eligibility Criteria
Inclusion
- Type 2 diabetes mellitus (diagnosed clinically) for at least 12 months
- Currently treated with premixed human insulin 50 BID for at least 3 months prior to screening visit (Visit 1)
- Currently treated with unchanged total daily dose of at least 1500 mg metformin or maximum tolerated dose at least 1000 mg/day metformin for at least 2 months prior to screening visit
- Glycosylated haemoglobin (HbA1c) 7.0% and 9.0% (both inclusive) (central laboratory)
Exclusion
- Treatment with any insulin secretagogue, alfa-glucosidase inhibitors, thiazolidinedione (TZD), dipeptidyl peptidase-4 (DPP-4) inhibitors and Glucagon-like peptide-1 (GLP-1) receptor agonists within the last 3 months prior to screening
- Previous use of any insulin other than premixed human insulin 50 BID within 3 months prior to Visit 1
- Previous use of insulin intensification treatment (premixed insulin thrice daily, basal bolus regimen, and continuous subcutaneous insulin infusion (CSII)) for more than 14 days
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2014
Estimated Enrollment :
161 Patients enrolled
Trial Details
Trial ID
NCT01892020
Start Date
June 1 2013
End Date
May 1 2014
Last Update
July 9 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing, Beijing Municipality, China, 100034